Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORICO Trial
2025-521677-14-00Phase 2Authorised
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in West Nile fever comparing Doravirine with Standard of care (2 arms). Primary endpoint: Percentage of patients achieving 4-fold decline in West Nile viremia. Planned start Oct 2025; status: authorised.
02
Drugs
doravirine
03
Conditions
West Nile fever
Beyond the preview
Go deeper on 2025-521677-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521677-14-00.